参考文献/References:
[1] Shoulson I. Where do we stand on neuroprotection? Where do we go from here?[J]. Mov Disord, 1998,13:46~48.
[2] Caparros D, Cabaret M, Codefroy O, et al. PET study and neuropsychological assessment of a long-lasting post-encephalitic parkinsonism[J]. J Neural Transm, 1998, 105:489~495.
[3] Turjanski, Lees AJ, Brooks DJ, et al. Dopaminergic function in patients with posttraumatic parkinsonism:An 18F-dopa PET study[J]. Neurology, 1997, 49:183~189.
[4] Burn DJ, Brooks DJ. Nigral dysfunction in drug-induced parkinsonism:An 18F-dopa PET study[J].Neurology, 1993, 43:552~556.
[5] Antonini A,Leenders KL, Vontobel P, et al.Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson’s disease[J]. Brain,1997, 120:2187~2195.
[6] Kim Y, Kim JW, Ito K, et al. Idiopathic parkinsonism with superimposed manganese exposure:utility of positron emission tomography[J].Neurotoxicology, 1999, 20:249~252.
[7] Ito K, Morrish PK, Rakshi JS, et al. Statistical parametric mapping with 18F-dopa PET shows bilaterally reduced striatal and nigral dopaminergic function in early Parkinson’s disease[J]. J Neurol Neurosurg Psychiatry, 1999, 66:754~758.
[8] Rakshi JS, Uema T, Ito K, et al. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson’s disease A 3D [18]dopa-PET study[J]. Brain, 1999, 122:1637~1650.
[9] Vingerhoets FJG, Snow BJ, Lee CS, et al.Longitudinal flurodopa positron emission tomography studies of the evolution of idiopathic parkinsonism[J].Ann Neurol, 1994, 36:759~764.
[10] Morrish PK, Sawle GV, Brooks DJ, et al. An 18F dopa-PET and clinical study of the rate of progressionin Parkinson’s disease[J]. Brain, 1996, 119:585~591.
[11] Morrish PK, Rakshi JS, Bailey DL, et al. Measuringthe rate of progression and estimating the preclinicalperiod of Parkinson’s disease with[18]-dopa PET[J]. J Neurol Neurosurg Psychiatry, 1998, 64:314~319.
[12] Hagell P, Schrag A, Piccini P, et al.Sequential bilateral transplantation in Parkinson’s disease:effects of the second graft[J]. Brain, 1999, 122:112~132.
[13] Defer GL, Geny C,Ricolfi F, et al. Long-termoutcome of unilaterally transplanted parkinsonian patients:I. Clinical approach[J]. Brain, 1996, 119:41~50.
相似文献/References:
[1]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
[2]许靖,李肖红,秦永德,等.帕金森病脑部葡萄糖代谢和脑多巴胺转运体PET显像特点的临床研究[J].国际放射医学核医学杂志,2016,40(5):338.[doi:10.3760/cma.j.issn.1673-4114.2016.05.003]
Xu Jing,Li Xiaohong,Qin Yongde,et al.Clinical study of brain glucose metabolism and brain dopamine transporter PET imaging in patients with Parkinson’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):338.[doi:10.3760/cma.j.issn.1673-4114.2016.05.003]
[3]闫卫红.Raclopride在帕金森病PET中的应用[J].国际放射医学核医学杂志,2005,29(1):27.
YAN Wei-hong.Application of raclopride PET in Parkinson’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(1):27.
[4]董爱生,田建明.PET、SPECT及MRS在帕金森病诊断中的应用[J].国际放射医学核医学杂志,2005,29(6):244.
DONG Ai-sheng,TIAN Jian-ming.The application of PET、SPECT and MRS in Parkinson’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(1):244.
[5]谭海波,刘兴党.PET在神经干细胞移植治疗帕金森病研究中的进展[J].国际放射医学核医学杂志,2004,28(6):253.
TAN Hai-bo,LIU Xing-dang.Progress of PET imaging in the study of neural stem cell transplantation treating Parkinson’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(1):253.
[6]田季雨.PET在帕金森病病理机制研究中的应用近况[J].国际放射医学核医学杂志,2003,27(2):53.
TIAN Ji-yu.Recent application of PET in the pathological mechanisms of PD[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(1):53.
[7]张海琴.中枢多巴胺转运蛋白显像剂99TcmTRODAT-1[J].国际放射医学核医学杂志,2001,25(3):100.
ZHANG Hai-qin.99Tcm-TRODAT-1: the central dopamine transporter imaging agent[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(1):100.
[8]孙文善.几种新型的中枢多巴胺转运蛋白显像剂[J].国际放射医学核医学杂志,2000,24(2):62.
SUN Wen-shan.Several new imaging agents for central dopamine transporter[J].International Journal of Radiation Medicine and Nuclear Medicine,2000,24(1):62.
[9]邓玮玮,张春银.放射性核素显像在帕金森病鉴别诊断中的应用[J].国际放射医学核医学杂志,2017,41(2):132.[doi:10.3760/cma.j.issn.1673-4114.2017.02.010]
Deng Weiwei,Zhang Chunyin.Application of radionuclide imaging on differential diagnosis of Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(1):132.[doi:10.3760/cma.j.issn.1673-4114.2017.02.010]
[10]于江,段玉清,毕常芬,等.多巴胺转运体PET显像剂11C-Altropane的研究进展[J].国际放射医学核医学杂志,2018,(1):74.[doi:10.3760/cma.j.issn.1673-4114.2018.01.014]
Yu Jiang,Duan Yuqing,Bi Changfen,et al.Progress of dopamine transporter PET imaging agent 11C-Altropane[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(1):74.[doi:10.3760/cma.j.issn.1673-4114.2018.01.014]